Key points are not available for this paper at this time.
Skin aging is caused by extrinsic and intrinsic factors and can lead to various aesthetic concerns and psychosocial stress. Exosome-based treatments have recently gained attention in the field of skin rejuvenation. This study aimed to retrospectively analyze the clinical efficacy of an exosome (CUREDOC EXOSOME REPAIR Advanced Solution Skin Booster, CUREDOC, Sejong, Korea) combined with microneedling treatment. We analyzed the medical records of 40 patients who received exosome skin booster (50 mcg/mL) and microneedling combination therapy at a single medical institution from January to March 2024. Physicians performed the treatment on each patient every 2 weeks for a total of 4 sessions. The physicians followed each patient for 8 weeks after the final treatment. The physicians evaluated each patient by taking clinical photographs, having each patient complete a satisfaction survey, assessing each patient using the Global Aesthetic Improvement Scale (GAIS), and documenting adverse events. The patient group had a mean age of 41.2 ± 6.3 years. The results of the study showed a high patient acceptance rate, with an overall satisfaction of 87.5%, an 82% intention to undergo repeat treatment, and an 85% willingness to recommend the treatment. According to the GAIS assessments, 85% of patients scored "improved" or greater. Adverse events were transient and mild, and there were no serious adverse reactions reported. Based on the results of this study, the combination of exosome skin booster and microneedling treatment can be considered a safe and effective option for improving facial aging.
Cho et al. (2025) studied this question.